Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 640979100 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
K2 HealthVentures Equity Trust LLC
13G/A
Amendment 2
|
3.1% |
5/15/2026
Event 3/31/2026
|
|
| K2 HealthVentures Equity Trust LLC | 3.1% | ||
| Parag Shah | 3.1% | ||
| Anup Arora | 3.1% | ||
|
Invus Global Management, LLC
13G/A
Amendment 1
|
4.7% |
5/4/2026
Event 3/31/2026
|
|
| Invus Public Equities, L.P. | 4.3% | ||
| Invus Public Equities Advisors, LLC | 4.3% | ||
| Invus Global Management, LLC | 4.3% | ||
| Siren, L.L.C. | 4.3% | ||
| Avicenna Life Sci Master Fund LP | 0.4% | ||
| Avicenna Life Sci Master GP LLC | 0.4% | ||
| Ulys, L.L.C. | 0.4% | ||
| Raymond Debbane | 4.7% | ||
|
ARCH Venture Fund XII, L.P.
13D/A
Amendment 4
|
18.7% |
4/1/2026
Event 3/30/2026
|
|
| ARCH Venture Fund VII, L.P. | 18.6% | ||
| ARCH Venture Fund VIII Overage, L.P. | 18.6% | ||
| ARCH Venture Fund X, L.P. | 18.6% | ||
| ARCH Venture Fund X Overage, L.P. | 18.6% | ||
| ARCH Venture Fund XII, L.P. | 18.6% | ||
| ARCH Venture Partners VII, L.P. | 18.6% | ||
| ARCH Venture Partners X, L.P. | 18.6% | ||
| ARCH Venture Partners X Overage, L.P. | 18.6% | ||
| ARCH Venture Partners XII, L.P. | 18.6% | ||
| ARCH Venture Partners VII, LLC | 18.6% | ||
| ARCH Venture Partners VIII, LLC | 18.6% | ||
| ARCH Venture Partners X, LLC | 18.6% | ||
| ARCH Venture Partners XII, LLC | 18.6% | ||
| Robert Nelsen | 18.6% | ||
| Keith Crandell | 18.6% | ||
| Clinton Bybee | 2.0% | ||
| Kristina Burow | 18.7% | ||
| Steven Gillis | 17.3% | ||
|
Invus Global Management, LLC
13G
|
5.4% |
2/19/2026
Event 2/13/2026
|
|
| Invus Public Equities, L.P. | 4.9% | ||
| Invus Public Equities Advisors, LLC | 4.9% | ||
| Invus Global Management, LLC | 4.9% | ||
| Siren, L.L.C. | 4.9% | ||
| Avicenna Life Sci Master Fund LP | 0.5% | ||
| Avicenna Life Sci Master GP LLC | 0.5% | ||
| Ulys, L.L.C. | 0.5% | ||
| Raymond Debbane | 5.4% | ||
|
K2 HealthVentures Equity Trust LLC
13G/A
Amendment 1
|
5.0% |
2/17/2026
Event 12/31/2025
|
|
| K2 HealthVentures Equity Trust LLC | 5.0% | ||
| Parag Shah | 5.0% | ||
| Anup Arora | 5.0% | ||
|
ARCH Venture Fund XII, L.P.
13D/A
Amendment 3
|
20.7% |
10/29/2025
Event 10/27/2025
|
|
| ARCH Venture Fund VII, L.P. | 20.6% | ||
| ARCH Venture Fund VIII Overage, L.P. | 20.6% | ||
| ARCH Venture Fund X, L.P. | 20.6% | ||
| ARCH Venture Fund X Overage, L.P. | 20.6% | ||
| ARCH Venture Fund XII, L.P. | 20.6% | ||
| ARCH Venture Partners VII, L.P. | 20.6% | ||
| ARCH Venture Partners X, L.P. | 20.6% | ||
| ARCH Venture Partners X Overage, L.P. | 20.6% | ||
| ARCH Venture Partners XII, L.P. | 20.6% | ||
| ARCH Venture Partners VII, LLC | 20.6% | ||
| ARCH Venture Partners VIII, LLC | 20.6% | ||
| ARCH Venture Partners X, LLC | 20.6% | ||
| ARCH Venture Partners XII, LLC | 20.6% | ||
| Robert Nelsen | 20.6% | ||
| Keith Crandell | 20.6% | ||
| Clinton Bybee | 2.3% | ||
| Kristina Burow | 20.7% | ||
| Steven Gillis | 19.2% | ||
|
K2 HealthVentures Equity Trust LLC
13G
|
6.6% |
8/11/2025
Event 5/9/2025
|
|
| K2 HealthVentures Equity Trust LLC | 6.6% | ||
| Parag Shah | 6.6% | ||
| Anup Arora | 6.6% | ||
|
FMR LLC
13G/A
Amendment 1
|
2.2% |
5/12/2025
Event 3/31/2025
|
|
| FMR LLC | 2.2% | ||
| Abigail P. Johnson | 2.2% | ||
| Paul L Berns 13G/A Amendment 1 | 5.1% |
2/13/2025
Event 12/31/2024
|
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 14 | 249 k | $327 k |
| 2026 Q2 | 124 | 76.0 M | $129 M |
| 2026 Q1 | 123 | 70.4 M | $137 M |
| 2025 Q4 | 111 | 63.1 M | $113 M |
| 2025 Q3 | 103 | 50.7 M | $92.3 M |
| 2025 Q2 | 106 | 56.0 M | $41.1 M |
| 2025 Q1 | 123 | 65.3 M | $65.3 M |
| 2024 Q4 | 166 | 80.3 M | $852 M |
| 2024 Q3 | 118 | 68.7 M | $907 M |
| 2024 Q2 | 104 | 72.7 M | $714 M |
| 2024 Q1 | 96 | 53.1 M | $730 M |
| 2023 Q4 | 68 | 44.4 M | $756 M |
| 2023 Q3 | 40 | 44.0 M | $620 M |